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(o the Editor: Noninvasive monitoring of cardiac gene therapy is
ritical to fully understand the biology of gene therapy in living
ubjects. We and others have monitored reporter gene expression
n the myocardium of small (1) and large (2) animals (reviewed in
eference 3). However, before these strategies are translated to the
linic, it is critical that they be tested using minimally invasive gene
elivery approaches similar to those used clinically.
We tested the hypothesis that reporter genes can be delivered
sing a minimally invasive strategy to the myocardium of a swine,
nd expression can then be imaged using combined positron
mission tomography-computed tomography (PET-CT).
Stanford’s Animal Care and Use Committee approved all
rocedures. Six domestic pigs (Pork Power Farms, Turlock,
alifornia) were used in the study. With sterile technique, 8-F
ascular sheaths placed in the carotid arteries were used for vascular
ccess. Percutaneous endomyocardial delivery systems (Biocardia,
nc., South San Francisco, California) (Fig. 1, left panel), placed
nto the sheaths, were used for fluoroscopy-guided delivery of
enes (1010 plaque-forming units) or vehicle (phosphate-buffered
Figure 1 Fluoroscopy-Guided Delivery of Genes
(Left) Percutaneous delivery system consisting of (A) steerable-guiding catheter a
ity, allowing catheter positioning in virtually any area of the left ventricular cavity. T
and then for the delivery of therapeutic material. (C) The infusion catheter is “scre
model. A left ventricular angiogram is performed for delineation of the left ventricu
firmed using contrast media (E), and gene therapy is then delivered.aline [PBS]) (Fig. 1, right panel) in 3 doses of 0.2 cc each.
entral mean arterial pressure (MAP) was measured. Forty-
ight hours after gene delivery, animals were dynamically imaged
fter intravenous administration of 18F-labeled 9-[4-fluoro-3-
hydroxymethyl)butyl]guanine (18F-FHBG; tracer) (4) using a
linical combined PET-CT system (Discovery LS, GE Medical
ystems, Milwaukee, Wisconsin) for a total scanning time of 180
in. Data are expressed as mean  SEM.
There were no significant differences in weight (control, 37.4 
.4 kg; gene therapy, 36.3  0.7 kg; p  NS), MAP (control,
07  11 mm Hg; gene therapy, 111  14 mm Hg; p  NS), or
eart rate (control, 90  7 beats/min; gene therapy, 95  9
eats/min; pNS) between the 2 groups. There was no morbidity
r mortality associated with the procedures. A total of 9.37 1.31
Ci of 18F-FHBG (in 5 ml of PBS) was administered per animal.
Figure 2 (top panel, A to D) shows a representative PET-CT
can of the gene therapy group. The CT images (Fig. 2A, top
anel) were used for anatomic localization, and 18F-FHBG uptake
Fig. 2B, top panel) was located in the area into which gene
helical needle infusion catheter. A steerable catheter provides maximum flexibil-
usion catheter is used first to confirm intramyocardial positioning of the catheter
inside the myocardium. (Right) Representative image of gene delivery in a swine
ocardial contour (D). Intramyocardial positioning of the helical catheter is con-nd (B)
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February 5, 2008:595–8herapy was delivered (anteroseptum) (Fig. 2C, top panel). Whole-
ody images (Fig. 2D, top panel) clearly showed the cardiac uptake
n chest and abdominal structures.
Animals from both groups had comparable 18F-FHBG uptake
n paraspinal muscles and the nondelivered myocardial wall (Figs.
E and 2F). Whereas control animals showed no distinct myocar-
ial tracer uptake, experimental animals had significantly increased
p 0.05) 18F-FHBG uptake (Figs. 2E and 2F, respectively). The
est myocardial signal/background (left ventricular) ratio was
btained 3 h post-injection (180 min, 4.63  1.4 vs. 90 min, 1.78
0.6; p  0.05). Autoradiography and microPET confirmed the
ncreased 18F-FHBG uptake in the anteroseptum of the gene
herapy animals.
Many different delivery methods have been developed for
ercutaneous cardiac delivery of gene therapy. The helical
eedle injection catheter system, used in this study, has the
heoretic advantages of endocardial engagement and helical
eedle-track and has been shown to have good acute delivery
uccess and retention (5). This delivery method has been
esigned to deliver material (e.g., genes, cells) to a specific and
Figure 2 Representative Positron EmissionTomography (PET) Computed Tomography (CT)
(Top) Image of gene therapy 48 h after percutaneous gene delivery (A to D).
(Bottom) Uptake of 18F-labeled 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine (stan-
dardized uptake value [SUV]) in (E) control (n  2) and (F) gene therapy (n 
4) groups. *p  0.05 compared to region of interest (ROI) (red circle). A 
anterior; B  bladder; CL  contralateral; I  intestines; K  kidney; L  left;
Li  liver; LV  left ventricular; P  posterior; R  right.elimited area. Multiple injections or vascular-based deliveryethods (e.g., intracoronary) may be more useful if the target
rea is a larger myocardial region or a specific coronary
istribution.
Adenoviral infection results in strong, albeit relatively short-
ived, transgene expression (6). For performing long-term longi-
udinal monitoring of therapy, other reporter gene strategies will
e needed, such as adeno-associated or gutless adenovirus (7,8).
PET has nanomolar to picomolar (1012 mol/l) sensitivity and
omographic capabilities, which makes PET the most suitable
maging modality for use in living subjects (compared with
agnetic resonance and single photon emission-computed tomog-
aphy) (9). Based on this study, 3 h after tracer administration
ppears to be a good time point for assessment of 18F-FHBG
ptake in the myocardium.
These studies will play a critical role in the monitoring of gene
herapy first in pre-clinical large animal models of cardiac disease
nd then in clinical therapeutic trials.
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2:S404–16.Letters to the Editorelationship Between Coronary
icrocirculatory Function and
ortic Stiffness in Diabetes
read with great interest the paper by Cortigiani et al. (1). This
ntriguing study confirmed that coronary flow reserve (CFR)
rovides independent prognostic information in diabetic and
ondiabetic patients with known or suspected coronary artery
isease (CAD) and negative dipyridamole stress echocardiography.
feel that a few additional comments are necessary.
It is well known that aortic distensibility and CFR as charac-
eristics of coronary microcirculatory function are reduced in
iabetes mellitus (DM) (2). Moreover, aortic stiffening may lead to
arly pulse wave reflection, causing an increase in central systolic
lood pressure (BP), a decrease in diastolic BP, and an increase in
ulse pressure. The elevation in systolic BP increases myocardial
xygen demand, reduces left ventricular ejection fraction, increases
entricular overload, and induces left ventricular hypertrophy.
ecause myocardial blood supply depends largely on pressure
hroughout diastole and the duration of diastole, the contemporary
ecrease in diastolic BP can compromise coronary perfusion, resulting
n subendocardial ischemia (3). Reduction in CFR was found in
atients with increased aortic stiffness compared with age-, gender-,
nd risk factor-matched controls with normal aortic distensibility (4).
hese findings direct our attention to consider aortic stiffness as an
mportant parameter affecting coronary hemodynamics.
The prognostic role of CFR and DM in patients with known or
uspected CAD has been confirmed, demonstrating that both
ariables are independently predictive of cardiovascular survival (5).
n recent studies, it has been demonstrated that CFR and indices
escribing aortic distensibility can be measured simultaneously by
chocardiography, helping us better understand their relationship
o each other (4,6). To see whether aortic distensibility could add
redictive value, patients with and without CAD were examined
7,8). It was found in patients with CAD that aortic distensibility
id not offer any added information in predicting cardiovascular
urvival. The potential complementary prognostic value of aortic
istensibility for prediction of cardiovascular mortality over CFR was
ound in patients without CAD and abnormal CFR, which should be
he topic of future research (8).
Interestingly, the number of studies evaluating the relationship
etween CFR and aortic stiffness in DM is limited (2,9,10).
lterations were found in CFR and aortic distensibility indices
ith correlations in diabetic patients with normal epicardialAD, aortic distensibility was reduced, but CFR was similar (9).
oreover, patients with aortic valve stenosis and type 2 DM had
imilar CFR and aortic distensibility indices compared with
ondiabetic patients with aortic valve stenosis (10).
It should be considered that theoretically the echocardiographic
valuation of aortic distensibility simultaneously with CFR mea-
urement is a relatively easy and patient-friendly method. Further
nvestigations are warranted to examine the direct effect of aortic
tiffness on coronary perfusion, especially in patients with DM.
urthermore, studies should evaluate the effect of antidiabetic
rugs on coronary perfusion and aortic elasticity as well. Finally,
tudies evaluating the prognostic role of a combination of indices
haracterizing aortic distensibility and CFR in DM are warranted.
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